BRIEF-Genelux Corp Announces Interim Results From Ongoing Lung Cancer Trials

Reuters
Jan 05
BRIEF-Genelux Corp Announces Interim Results From Ongoing Lung Cancer Trials

Jan 5 (Reuters) - Genelux Corp GNLX.O:

  • GENELUX CORP - ANNOUNCES INTERIM RESULTS FROM ONGOING LUNG CANCER TRIALS

  • GENELUX- IN ADVANCED OR METASTATIC RECURRENT NSCLC, OBSERVED ANTI-TUMOR ACTIVITY IN INITIAL DOSE COHORT & OLVI-VEC GENERALLY WELL TOLERATED (PHASE 2 VIRO-25)

  • GENELUX CORP - TOPLINE DATA FROM PHASE 3 OVARIAN CANCER TRIAL (ONPRIME/GOG-3076) IN SECOND HALF OF 2026

Source text: ID:nGNXbV0bkb

Further company coverage: GNLX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10